Microsoft Excel LibreOffice Calc

Liquidity Analysis

Difficulty: Beginner


Ratios (Summary)

Celgene Corp., liquidity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Current ratio 4.99 3.67 4.77 4.60 3.88
Quick ratio 4.67 3.24 4.05 4.13 3.47
Cash ratio 4.03 2.69 3.33 3.57 2.92

Based on: 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-13).

Ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Celgene Corp.'s current ratio deteriorated from 2015 to 2016 but then improved from 2016 to 2017 exceeding 2015 level.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Celgene Corp.'s quick ratio deteriorated from 2015 to 2016 but then improved from 2016 to 2017 exceeding 2015 level.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Celgene Corp.'s cash ratio deteriorated from 2015 to 2016 but then improved from 2016 to 2017 exceeding 2015 level.

Current Ratio

Celgene Corp., current ratio calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Current assets 14,892  10,868  9,401  9,713  7,551 
Current liabilities 2,987  2,959  1,969  2,112  1,946 
Ratio
Current ratio1 4.99 3.67 4.77 4.60 3.88
Benchmarks
Current Ratio, Competitors
Abbott Laboratories 2.26 4.02 1.54 1.45 2.02
AbbVie Inc. 1.28 1.65 1.50 1.41 2.59
Allergan PLC 1.16 2.27 1.03 1.37 1.35
Amgen Inc. 5.49 4.11 4.44 4.95 3.44
Biogen Inc. 2.34 2.55 2.60 2.11 1.81
Bristol-Myers Squibb Co. 1.55 1.55 1.30 1.73 1.52
Eli Lilly & Co. 1.32 1.37 1.53 1.09 1.47
Gilead Sciences Inc. 2.74 2.22 2.50 3.07 1.15
Johnson & Johnson 1.41 2.47 2.17 2.36 2.20
Merck & Co. Inc. 1.33 1.78 1.55 1.77 2.00
Pfizer Inc. 1.35 1.25 1.49 2.67 2.41
Regeneron Pharmaceuticals Inc. 3.82 2.56 3.59 3.31 6.01
Current Ratio, Sector
Pharmaceuticals & Biotechnology 1.82 2.14 1.92 2.19 2.13
Current Ratio, Industry
Health Care 1.58 1.75 1.65 1.86 1.90

Based on: 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-13).

2017 Calculations

1 Current ratio = Current assets ÷ Current liabilities
= 14,892 ÷ 2,987 = 4.99

Ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Celgene Corp.'s current ratio deteriorated from 2015 to 2016 but then improved from 2016 to 2017 exceeding 2015 level.

Quick Ratio

Celgene Corp., quick ratio calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Cash and cash equivalents 7,013  6,170  4,880  4,122  3,234 
Marketable securities available-for-sale 5,029  1,800  1,672  3,425  2,453 
Accounts receivable, net of allowances 1,921  1,621  1,421  1,167  1,061 
Total quick assets 13,963  9,590  7,973  8,713  6,748 
Current liabilities 2,987  2,959  1,969  2,112  1,946 
Ratio
Quick ratio1 4.67 3.24 4.05 4.13 3.47
Benchmarks
Quick Ratio, Competitors
Abbott Laboratories 1.67 3.31 1.04 0.76 1.27
AbbVie Inc. 0.89 1.14 1.21 1.06 2.00
Allergan PLC 0.95 2.00 0.42 0.52 0.53
Amgen Inc. 4.98 3.68 3.97 4.22 2.78
Biogen Inc. 1.78 1.94 1.93 1.54 1.31
Bristol-Myers Squibb Co. 1.30 1.27 1.05 1.26 0.61
Eli Lilly & Co. 0.91 0.98 1.04 0.77 1.06
Gilead Sciences Inc. 2.52 1.78 2.07 2.56 0.67
Johnson & Johnson 1.04 2.04 1.77 1.76 1.59
Merck & Co. Inc. 0.83 1.24 1.04 1.19 1.38
Pfizer Inc. 0.93 0.84 1.07 2.07 1.79
Regeneron Pharmaceuticals Inc. 2.98 2.13 3.10 2.93 5.52
Quick Ratio, Sector
Pharmaceuticals & Biotechnology 1.42 1.69 1.48 1.63 1.50
Quick Ratio, Industry
Health Care 1.23 1.38 1.27 1.39 1.36

Based on: 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-13).

2017 Calculations

1 Quick ratio = Total quick assets ÷ Current liabilities
= 13,963 ÷ 2,987 = 4.67

Ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Celgene Corp.'s quick ratio deteriorated from 2015 to 2016 but then improved from 2016 to 2017 exceeding 2015 level.

Cash Ratio

Celgene Corp., cash ratio calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Cash and cash equivalents 7,013  6,170  4,880  4,122  3,234 
Marketable securities available-for-sale 5,029  1,800  1,672  3,425  2,453 
Total cash assets 12,042  7,970  6,552  7,547  5,687 
Current liabilities 2,987  2,959  1,969  2,112  1,946 
Ratio
Cash ratio1 4.03 2.69 3.33 3.57 2.92
Benchmarks
Cash Ratio, Competitors
Abbott Laboratories 1.08 2.82 0.67 0.42 0.85
AbbVie Inc. 0.59 0.66 0.77 0.73 1.44
Allergan PLC 0.65 1.68 0.13 0.05 0.10
Amgen Inc. 4.62 3.40 3.62 3.86 2.44
Biogen Inc. 1.10 1.43 1.33 0.83 0.70
Bristol-Myers Squibb Co. 0.71 0.72 0.53 0.88 0.36
Eli Lilly & Co. 0.55 0.55 0.54 0.43 0.61
Gilead Sciences Inc. 2.19 1.29 1.48 1.76 0.34
Johnson & Johnson 0.60 1.59 1.38 1.32 1.14
Merck & Co. Inc. 0.46 0.83 0.70 0.84 0.98
Pfizer Inc. 0.66 0.57 0.79 1.67 1.39
Regeneron Pharmaceuticals Inc. 1.24 0.84 1.29 1.38 2.32
Cash Ratio, Sector
Pharmaceuticals & Biotechnology 1.03 1.29 1.08 1.21 1.08
Cash Ratio, Industry
Health Care 0.85 0.97 0.88 0.99 0.96

Based on: 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-13).

2017 Calculations

1 Cash ratio = Total cash assets ÷ Current liabilities
= 12,042 ÷ 2,987 = 4.03

Ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Celgene Corp.'s cash ratio deteriorated from 2015 to 2016 but then improved from 2016 to 2017 exceeding 2015 level.